Armata Pharmaceuticals Inc (ARMP)
Armata Pharmaceuticals Inc is a common stock listing on the NYSE under the symbol ARMP. The company is a clinical-stage biotechnology business focused on developing targeted bacteriophage therapeutics for antibiotic-resistant infections. Its pipeline includes AP-SA02 for Staphylococcus aureus bacteremia, AP-PA02 for Pseudomonas aeruginosa, and AP-PA03 for pneumonia. Armata is also involved in a research collaboration with Merck Sharp & Dohme Corp. to develop synthetic bacteriophage candidates aimed at undisclosed infectious disease agents. The company is based in Los Angeles, California, and operates as a subsidiary of Innoviva, Inc.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-ARMP
|
$2.48
|
-17.4% Downside
|
Fair
|
$17.50
|
483.3% Upside
|
Bargain
|
Weak
|
0.0%
|
November 18, 2026
|
20.1x
|
111.5 M
|
401.5 M
|
72.9%
|
32.0%
|
-12.9
|
13.4%
|
